Exosome Therapy in Stroke

Phase 2

Recruiting

• Conditions: Ischemic Stroke.; Cerebellar stroke syndrome; G46.4

• Registration Number: IRCT20141224020427N4
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 5

Inclusion Criteria

Male acute ischemic patients aged 40-80 years with symptoms of acute cerebral infarction of less than 24h from stroke onset.
Patients with a measurable focal neurological that must persist to the time of treatment without clinically meaningful improvement
Patients must have computerized tomography (CT) and / or magnetic resonance imaging (MRI) compatible with the clinical diagnosis of acute ischemic stroke in the territory of the middle cerebral artery before being included in the study.
Patients must have a score on the NIH Stroke Scale 8-24,
Obtaining informed consent signed

Exclusion Criteria

Comatose patients.
brain tumour, cerebral oedema with compression of ventricles, cerebellar infarction or brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage.
alcohol use Active infectious disease, including HIV, hepatitis B, Hepatitis
patients with dementia
Specify clinical conditions
Patients who are participating in another clinical trial.
Inability or unwillingness of individual for giving written informed consent.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: 3, 30 and 90 days after injection. Method of measurement: Thermometer.;High sensitivity C-Reactive protein. Timepoint: 3, 30, 90 days after injection. Method of measurement: Colorimetric Method.;Recurrent Stroke. Timepoint: 3, 30, 90 days after injection. Method of measurement: computerized tomography (CT).;Hemorrhagic transformation. Timepoint: 3, 30, 90 days after injection. Method of measurement: computerized tomography (CT).;Brain Oedema. Timepoint: 3, 30 , 90 days after injection. Method of measurement: computerized tomography (CT).